Literature DB >> 30082157

Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.

In Hye Song1, Kyu-Rae Kim2, Sehun Lim3, Seok-Hyung Kim4, Chang Ohk Sung5.   

Abstract

The epithelial-mesenchymal transition (EMT) is known to be associated with carcinoma invasion and metastasis. Previous studies have demonstrated that the expression of EMT-related proteins in carcinoma cells in many organs is associated with a higher histologic grade and a poor prognosis. However, the clinical significance of EMT in ovarian cancers is controversial. Formalin-fixed and paraffin-embedded tumor samples of 198 high-grade serous carcinomas (HGSCs) and 13 serous borderline tumors or low-grade serous carcinomas (SBT/LGSCs) of the ovary were analyzed. EMT phenotype marker expression, including claudin 4, E-cadherin, N-cadherin, α-smooth muscle actin (α-SMA) and vimentin, and EMT related transition factor expression, including paired-related homeobox 1 (PRRX1), SLUG, SNAI1, and TWIST1, were evaluated by immunohistochemistry. EMT phenotype was classified into three groups including complete EMT phenotype, incomplete EMT phenotype, and epithelial phenotype according to epithelial and mesenchymal marker expression. EMT phenotypes varied in HGSC (Complete phenotype, 32.3%; Incomplete phenotype, 42.9%; epithelial phenotype, 24.7%) compared with SBT/LGSC. EMT phenotype and each EMT phenotype markers were not significantly associated with patient survival of HGSCs in multivariate analysis. However transition factor, SLUG expression, correlated with advanced disease and SLUG expression was an independent predictor of poor overall survival in HGSC. EMT related transition factor expression like SLUG is more important in association with clinical outcome than EMT phenotype itself in HGSC.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Epithelial-mesenchymal transition; Ovarian neoplasms; Phenotype; SLUG

Mesh:

Substances:

Year:  2018        PMID: 30082157     DOI: 10.1016/j.prp.2018.07.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells.

Authors:  Dongli Liu; Gunnar F Kaufmann; James B Breitmeyer; Kristie-Ann Dickson; Deborah J Marsh; Caroline E Ford
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

2.  FKBP51 promotes migration and invasion of papillary thyroid carcinoma through NF-κB-dependent epithelial-to-mesenchymal transition.

Authors:  Ying Gao; Elham Elamin; Rongfang Zhou; Huili Yan; Shuang Liu; Shengnan Hu; Jing Dong; Muyun Wei; Linying Sun; Yueran Zhao
Journal:  Oncol Lett       Date:  2018-09-27       Impact factor: 2.967

3.  Adipose-Derived Stem Cells Facilitate Ovarian Tumor Growth and Metastasis by Promoting Epithelial to Mesenchymal Transition Through Activating the TGF-β Pathway.

Authors:  Xiaowu Liu; Guannan Zhao; Xueyun Huo; Yaohong Wang; Gabor Tigyi; Bing-Mei Zhu; Junming Yue; Wenjing Zhang
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

4.  Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.

Authors:  Lan Dai; Jixiang Niu; Yanli Feng
Journal:  J Cell Mol Med       Date:  2019-10-30       Impact factor: 5.310

5.  Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.

Authors:  Sonia Capellero; Jessica Erriquez; Chiara Battistini; Roberta Porporato; Giulia Scotto; Fulvio Borella; Maria F Di Renzo; Giorgio Valabrega; Martina Olivero
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.